Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

Figures & data

Figure 1 Baseline and follow-up best corrected visual acuity (BCVA) measured in both the groups.

Figure 2 Changes in best corrected visual acuity (BCVA) in eyes of both the groups of the study.

Table 1 Best corrected visual acuity (measured by Snellen decimal notation) at baseline and at benchmark follow-up visits in both the groups

	Baseline	1st month	3rd month	6th month	12th month
Aflibercept group	0.17±0.05 (0.1–0.25)	0.39±0.21 (0.1–0.7)	0.35±0.2 (0.05–0.7)	0.37±0.24 (0.2–0.8)	0.42±0.28 (0.1–0.8)
Ranibizumab group	0.18±0.04 (0.1–0.3)	0.34±0.19 (0.1–0.7)	0.33±0.19 (0.1–0.6)	0.41±0.19 (0.05–0.7)	0.37±0.23 (0.05–0.7)
P-value	0.9	0.83	0.7	0.87	0.27

Note: The data in this table are presented as mean ± SD (range).

Figure 3 Baseline and follow-up central macular thickness (CMT) measured in both the groups.

Table 2 Central macular thickness (measured in µm) at baseline and at benchmark follow-up visits in both the groups

	Baseline	1st month	3rd month	6th month	12th month
Aflibercept group	465.29±33.7 (411–535)	365.4±72.2 (256–499)	370.54±83.6 (250–527)	391.7±85.8 (245–536)	360.8±85.7 (265–501)
Ranibizumab group	471.5±34.4 (402–516)	388.06±77.3 (245–519)	394.3±84.8 (246–578)	360.1±74.4 (236–529)	387.3±87.8 (253–522)
P-value	0.65	0.2	0.24	0.1	0.2

Note: The data in this table are presented as mean ± SD (range).